Literature DB >> 11170010

MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system.

I A Scarisbrick1, P J Isackson, B Ciric, A J Windebank, M Rodriguez.   

Abstract

The goal of the present investigation was to determine the regional and cellular specific expression patterns of the newly identified serine protease, myelencephalon-specific protease (MSP), in the adult human brain (Scarisbrick et al. [1997b] J. Neurosci. 17:8156-8168). To assess the potential scope of MSP activity, Northern blot techniques were used to determine the relative abundance of MSP mRNA in 16 different adult human brain regions, and in the brain and peripheral tissues of the midgestation human fetus. The regional and temporal specific expression patterns of MSP mRNA were directly compared with those of tissue plasminogen activator (tPA), a serine protease strongly implicated in the development, ongoing plasticity, and response of the nervous system to injury and disease. mRNA encoding each protease was distributed widely throughout the normal adult human central nervous system (CNS), but the expression of each was only partially overlapping. Additionally, compared with tPA, MSP exhibited a more restricted distribution and delayed developmental onset. By immunohistochemical localization, MSP was present at moderate to high levels in neurons and oligodendroglia of the adult human brain, at a level closely resembling the relative abundance indicated by Northern blot. MSP was most abundantly expressed in the spinal cord, hippocampus, substantia nigra, and basal ganglia. The robust expression of MSP in clinically significant regions of the adult human CNS indicates that further study of this protease in terms of both normal brain physiology and neurodegenerative disorders is warranted. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170010

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  22 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

3.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

Review 4.  Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration.

Authors:  Rodolphe Perrot; Raphael Berges; Arnaud Bocquet; Joel Eyer
Journal:  Mol Neurobiol       Date:  2008-07-23       Impact factor: 5.590

5.  Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.

Authors:  Joshua E Burda; Maja Radulovic; Hyesook Yoon; Isobel A Scarisbrick
Journal:  Glia       Date:  2013-07-08       Impact factor: 7.452

6.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

7.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

8.  Protease activated receptor 2 controls myelin development, resiliency and repair.

Authors:  Hyesook Yoon; Maja Radulovic; Grant Walters; Alex R Paulsen; Kristen Drucker; Phillip Starski; Jianmin Wu; David P Fairlie; Isobel A Scarisbrick
Journal:  Glia       Date:  2017-09-18       Impact factor: 7.452

9.  Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group.

Authors:  Guyan Liang; Xin Chen; Suzanne Aldous; Su-Fen Pu; Shujaath Mehdi; Elaine Powers; Andrew Giovanni; Sathapana Kongsamut; Tianhui Xia; Ying Zhang; Rachel Wang; Zhongli Gao; Gregory Merriman; Larry R McLean; Isabelle Morize
Journal:  ACS Med Chem Lett       Date:  2012-01-11       Impact factor: 4.345

10.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.